




Pamidronate–osteoporosis · 88.69% · DM




Alendronate—osteoporosis · 88.50% · DM




Risedronate–osteoporosis · 88.11% · DM




Esomeprazole–Barrett's esophagus · 82.31% · DM




lbandronate–Paget's disease of bone · 80.26% · nan




Glyburide—type 2 diabetes mellitus · 79.96% · DM




Omeprazole–Barrett's esophagus · 78.68% · DM




Alendronate–Paget's disease of bone · 76.98% · DM




Etidronic acid–Paget's disease of bone · 74.88% · DM




Pamidronate–Paget's disease of bone · 72.96% · DM




Furosemide-hypertension · 71.71% · DM




Olsalazine—Crohn's disease · 66.53% · nan




Paricalcitol-osteoporosis · 60.35% · nan




Ethotoin—epilepsy syndrome · 58.85% · nan




Quazepam—epilepsy syndrome · 57.00% · nan




Alprazolam—epilepsy syndrome · 56.49% · nan




Paricalcitol-psoriasis · 56.46% · nan



Zidovudine–hepatitis B · 56.05% · nan



Tafluprost–glaucoma · 55.59% · nan



Carboprost Tromethamine—glaucoma · 55.15% · nan

